OVERVIEW
Happy Saturday
Welcome to the Stocks Top 25 Newsletter this week!
The Stocks Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Here are the Stocks Top 25 Lists for this week:
S&P 500
Top 25 S&P 500
The S&P 500 Top 25 list came up 3.42%compared to the weekly S&P 500 index -0.38%
Newcomers are in blue. Grey names at the bottom were kicked out of last week’s list.
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list performed 0.60% compared to the weekly Nasdaq 100 index -0.92%
Newcomers are in blue. Grey names at the bottom were kicked out of last week’s list.
RUSSELL 2000
The Growth-Centric Russell 2000 🦐
The Russell 2000 Top 25 list was 5.46%compared to the weekly Russell 2000 index 2.04%
Newcomers are in blue. Grey names at the bottom were kicked out of last week’s list.
Top Dawg Of The Week
The Top 25 list's Top Dawg was $IBRX ( ▲ 39.75% ) , climbing a whopping 136%!!
Biotech and Healthcare Breakthroughs
Shares of ImmunityBio jumped nearly 50% after the company announced that enrollment for its QUILT-2.005 bladder cancer trial surpassed internal expectations and is now 85% complete. Preliminary data shows that combining ANKTIVA with standard BCG therapy significantly extends the duration of complete response in patients, with an 85% response rate at six months compared to just 57% for the BCG-only group. The company is now on track to submit a Biologics License Application to the FDA by the end of 2026.
The news hit the wires before the market opened on Friday.
ImmunityBio ($IBRX): The company officially released the news at 7:00 am ET on Friday, Jan 16. The stock soared nearly 40% (briefly touching 50% in intraday trading) as investors reacted to the 85% trial enrollment and the 700% jump in Anktiva revenue.
